Centocor

News Centocor

• MorphoSys Announces Clinical Milestone from Strategic Alliance

  MorphoSys AG announced that it will receive a milestone payment from Novartis in connection with the initiation of a phase 1 clinical trial, using a HuCAL-derived, fully human antibody in the therapeutic area of musculoskeletal diseases. The news represents the second HuCAL-derived antibody to achi more

• MorphoSys: First of up to Six Expected Clinical Phase 1 Milestones During 2010

  MorphoSys AG announced that it will receive a clinical milestone payment from Centocor Ortho Biotech Inc. (formerly known as: Centocor, Inc.) in connection with the initiation of a phase 1 clinical trial of a HuCAL-derived antibody in the therapeutic area of inflammatory and autoimmune diseases. Th more

• Genetic Technologies appoints Lewis J. Stuart as General Manager of its New North American Molecular Diagnostics Business

  Genetic Technologies Limited announced the appointment of Mr. Lewis Stuart as General Manager of its North American molecular diagnostics business. The new division is the result of the Company’s recent acquisition of US assets including BREVAGen™, a fully validated risk assessment test for non-her more

Publications Centocor

• Utilization of Site-Specific Recombination for Generating Therapeutic Protein Producing Cell Lines

  The AttSite® Recombinase Technology from Intrexon, Blacksburg, VA, utilizes specific DNA sequences and proprietary recombinase enzymes to catalyze the insertion of a gene of interest at a specific location in the host cell genome. Using this technology, we have developed Chinese Hamster Ovary (CHO) more

Websites Centocor